ClinicalTrials.gg
RecruitingNCT07539324DCBMultivesselUpdated Oct 9, 2026

Clinical Impact of DCB-based Versus DES-based Intervention in Patients With MVCAD

An interventional study of GENOSS® DCB (Paclitaxel-coated PTCA balloon catheter) and Contemporary Drug-Eluting Stents (DES) in Multi Vessel Coronary Artery Disease and Percutaneous Coronary Intervention, sponsored by Genoss Co., Ltd.. Recruiting at 1 site in South Korea. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Genoss Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 9, 2026Now RecruitingFirst site in South Korea+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
892
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Coronary Artery Disease by Genoss Co., Ltd. — 6 open to participants now, 6 under way, none of them phase 3. Coronary Artery Disease · Genoss Co., Ltd..

Started
2026
the only one that year
No phase
4 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Coronary Artery Disease by Genoss Co., Ltd., this one is the only one that started in 2026, is one of 4 with no phase, and was the 10th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

6 of the 10 studies in Coronary Artery Disease by Genoss Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Coronary Artery Disease by Genoss Co., Ltd., or all of them as a file.
02

Study summary

This study aimes to compare the clinical outcomes of drug-coated balloon-based percutaneous coronary intervention (DCB-based PCI) and drug-eluting stent-based percutaneous coronary intervention (DES-based PCI) in patients with multivessel coronary artery lesions measuring 2.25 mm to 4.0 mm in diameter through a prospective, multicenter, active-controlled, randomized, investigator-initiated clinical trial.

Read the detailed description

This study is a prospective, multicenter, active-controlled, randomized, single-blind, investigator-initiated clinical trial in patients with multivessel coronary artery disease.

The clinical outcomes of the DCB-based PCI group and the DES-based PCI group, assigned through 1:1 random assignment, will be compared, and approximately 9 hospitals will participate.

The primary endpoint is the time to the first occurrence of a Net Clinical Outcome (NCO) within 12 months after randomization, and the secondary endpoint is the Net Clinical Outcome (NCO) through 36 months after the index procedure.

Successful lesion preparation for DCB treatment will not be used as an eligibility criterion before randomization. Lesion preparation will be performed after randomization according to the assigned treatment strategy and the protocol-specified procedural requirements.

03

Conditions studied

  • Multi Vessel Coronary Artery Disease
  • Percutaneous Coronary Intervention
04

Who can participate

The criteria were revised on the registry on Oct 9, 2026. See what changed

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all of the following inclusion criteria to be eligible for participation in this clinical study.

  1. Adults aged ≥20 years with stable angina, silent myocardial ischemia, unstable angina, or non-ST-segment elevation myocardial infarction (NSTEMI).
  2. Patients with ST-segment elevation myocardial infarction (STEMI) who have undergone successful and uncomplicated primary percutaneous coronary intervention (PCI), are at least 48 hours after the index procedure, and have no evidence of thrombus in the lesion(s) intended for treatment.
  3. Patients with multivessel coronary artery disease, defined as ≥50% diameter stenosis by coronary angiography, in whom the investigator determines that PCI is indicated in at least two major epicardial coronary arteries.
  4. Patients with a reference vessel diameter (RVD) of ≥2.25 mm and ≤4.0 mm, as assessed by coronary angiography.
  5. Patients in whom the investigator determines, based on coronary angiographic findings and clinical assessment, that PCI of the target lesion(s) is technically feasible.
  6. Patients who voluntarily provide written to participate in the clinical trial and are willing and able to comply with the study requirements.

Exclusion criteria

Exclusion Criteria:

Patients meeting any of the following criteria will be excluded from enrollment.

  1. Cardiogenic shock or the need for mechanical or pharmacological circulatory support.
  2. of ≤2 years due to concomitant medical conditions.
  3. Current participation in, or planned participation in, another interventional clinical trial, excluding observational studies.
  4. Pregnant women or women of .
  5. Known or allergy to contrast media, L-605 cobalt-chromium (Co-Cr) alloy, PLA or PLGA polymers, shellac, Vitamin E-TPGS, paclitaxel, or sirolimus.
  6. A target lesion located within a saphenous vein graft or an arterial graft.
  7. Patients in whom the investigator determines that PCI cannot be performed because of the anatomical characteristics of the target vessel or lesion or the patient's clinical condition.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
892 participants (estimated)

Study arms

  • Experimental
    GENOSS® DCB

    Paclitaxel-coated PTCA Balloon Catheter

    Device: GENOSS® DCB (Paclitaxel-coated PTCA balloon catheter)

  • Active comparator
    Contemporary Drug-Eluting Stents (DES)

    All-comer current-generation biodegradable or durable polymer-based drug-eluting stents (DES)

    Device: Contemporary Drug-Eluting Stents (DES)

Interventions

  • DeviceGENOSS® DCB (Paclitaxel-coated PTCA balloon catheter)

    GENOSS DCB is designed to improve the lumen diameter and to reduce restenosis in the treatment of lesions in native coronary arteries. GENOSS DCB has been demonstrated to reduce restenosis for the treatment of in-stent restenosis and de-novo lesions in coronary arteries narrowed by atherosclerosis. GENOSS DCB is designed to improve the lumen diameter and to reduce restenosis in the treatment of lesions in native coronary arteries. GENOSS DCB has been demonstrated to reduce restenosis for the treatment of in-stent restenosis and de-novo lesions in coronary arteries narrowed by atherosclerosis. GENOSS DCB's active drug coating is located on the surface of the balloon, which contains 3ug Paclitaxel per 1mm2. The drug is embedded in a physiologically harmless and degradable delivery matrix (main component: shellac and vitamin E-TPGS).

  • DeviceContemporary Drug-Eluting Stents (DES)

    Contemporary drug-eluting stents (DES) with either biodegradable or non-biodegradable (durable) polymer coatings, covering all regulatory-approved, thin-strut metal platforms.

06

What researchers measure

Primary outcomes

  1. Net Clinical outcome (NCO)

    The primary endpoint is the time to the first occurrence of a Net Clinical Outcome (NCO) within 12 months after randomization. NCO is defined as a composite of all-cause death, non-fatal myocardial infarction, clinically driven target-vessel revascularization (CD-TVR), or BARC type 2-5 bleeding. The time-to-event will be measured from the date of randomization to the date of the first occurrence of any component of the NCO.

    Time frame: the time to the first occurrence of a Net Clinical Outcome (NCO) within 12 months after randomization.

Secondary outcomes

  1. Net Clinical outcome (NCO)

    Net Clinical Outcome (NCO) is defined as a composite of all-cause death, non-fatal myocardial infarction, clinically driven target vessel revascularization (TVR), and BARC (Bleeding Academic Research Consortium) type 2 to 5 bleeding.

    Time frame: at 24, and 36 months after procedure

  2. Major adverse cardiovascular events (MACEs)

    Major adverse cardiovascular events (MACEs) are defined as a composite of cardiac death, non-fatal myocardial infarction, definite stent thrombosis, and stroke.

    Time frame: at 24, and 36 months after procedure

  3. Major adverse cardiac events (MACE)

    Major adverse cardiac events (MACE) is defined as a composite of all-cause death, non-fatal myocardial infarction (MI), and target vessel revascularization (TVR).

    Time frame: at 24, and 36 months after procedure

  4. Major bleeding

    Major bleeding is defined as Bleeding Academic Research Consortium (BARC) type 3 to 5 bleeding.

    Time frame: at 24, and 36 months after procedure

  5. All-cause death

    Time frame: at 24, and 36 months after procedure

  6. Cardiac death

    Cardiac death is defined according to the Academic Research Consortium (ARC) criteria and includes the following: * Death related to myocardial infarction (MI) * Sudden cardiac death (SCD) * Death due to heart failure * Death due to fatal arrhythmia * Other deaths without a clearly documented non-cardiac cause (Deaths of unknown cause are classified as cardiac deaths)

    Time frame: at 24, and 36 months after procedure

  7. Myocardial infarction

    ST elevation myocardial infarction and Non-ST elevation myocardial infarction will be evaluated. 1. Spontaneous MI (Type 1 MI) : Defined as a rise and/or fall of cardiac troponin with at least one value exceeding the 99th percentile upper reference limit, accompanied by clinical evidence of myocardial ischemia. 2. Periprocedural MI (Type 4a MI) : Defined as an elevation of cardiac troponin to ≥5 times the 99th percentile upper reference limit following PCI, accompanied by clinical evidence of ischemia (chest pain, ECG changes, imaging abnormalities, etc.). ST-segment elevation status (STEMI vs. NSTEMI) will be recorded as supplementary information but is not included in the primary endpoint definition.

    Time frame: at 24, and 36 months after procedure

  8. Target vessel-myocardial infaction (TV-MI)

    Time frame: at 24, and 36 months after procedure

  9. Target lesion revascularization (TLR)

    Time frame: at 24, and 36 months after procedure

  10. Target vessel revascularization (TVR)

    Time frame: at 24, and 36 months after procedure

  11. Definite or probable stent thrombosis

    Time frame: at 24, and 36 months after procedure

  12. Ischemic or hemorrhagic stroke

    Time frame: at 24, and 36 months after procedure

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2030, 51 months after the start.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 51 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Apr 2026 → Sep 2026 and completion Jul 2032 → Dec 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
Apr 20, 2026
StartActual
Sep 28, 2026was Apr 2026
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2032was Jul 2032
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 9, 2026
Sites
1 site added — first site in South Korea
Show site
  • Ulsan University Hospital · Ulsan, South Korea
Oct 9, 2026
Start date
Apr 15, 2026→Sep 28, 2026 (actual)
Oct 9, 2026
Study completion
Jul 31, 2032→Dec 31, 2032
Oct 9, 2026
Eligibility
5 inclusion criteria edited, 2 added, 1 removed; 6 exclusion criteria edited, 2 added, 1 removed
What changed in the criteria
Inclusion criteria
  • AddedPatients must meet all of the following inclusion criteria to be eligible for participation in this clinical study.
  • EditedMale or female adultsAdults aged ≥20 years or older with stable angina, silent myocardial ischemia, unstable angina, or non-ST-segment elevation myocardial infarction (NSTEMI).
  • EditedIn cases ofPatients with ST-segment elevation myocardial infarction (STEMI), patients who have undergone successful and uncomplicated primary percutaneous coronary intervention (PCI) without complications,, are at least 48 hours post-after the index procedure, and whose target lesion(s) showhave no evidence of thrombus in the lesion(s) intended for treatment.
  • EditedPatients with multivessel coronary artery disease, defined as angiographic≥50% diameter stenosis of 50%by coronary angiography, in whom the investigator determines that PCI is indicated in at least two major epicardial coronary arteries requiring PCI as determined by the investigator.
  • EditedReferencePatients with a reference vessel diameter (RVD) of the target lesion(s) between ≥2.25 mm and ≤4.0 mm, as assessed by visual estimation or quantitative coronary angiography (QCA).
  • RemovedTarget lesions suitable for treatment with either drug-eluting stents (DES) or drug-coated balloons (DCB).
  • AddedPatients in whom the investigator determines, based on coronary angiographic findings and clinical assessment, that PCI of the target lesion(s) is technically feasible.
  • EditedPatients who have voluntarily providedprovide written informed consent to participate in the clinical trial and are willing and able to comply with all protocol-specifiedthe study requirements.
Exclusion criteria
  • AddedPatients meeting any of the following criteria will be excluded from enrollment.
  • EditedCardiogenic shock or patients requiringthe need for mechanical or pharmacological circulatory support.
  • EditedPatients with a lifeLife expectancy of less than ≤2 years due to comorbidconcomitant medical conditions.
  • ChangedBefore Patients who are currently participating or planning to participate in other interventional clinical trials, excluding observational studies.Now Current participation in, or planned participation in, another interventional clinical trial, excluding observational studies.
  • EditedWomen who are pregnantPregnant women or havewomen of childbearing potential.
  • EditedPatients with a knownKnown hypersensitivity or allergy to contrast media, L-605 Cobaltcobalt-Chromiumchromium (Co-Cr) alloy, PLA andor PLGA polymers, shellac, Vitamin E-TPGS, paclitaxel, or sirolimus.
  • EditedPatients with aA target lesion located within a saphenous vein graft (SVG) or an arterial graft.
  • RemovedPatients with target vessels/lesions that are excessively tortuous, angulated, or severely calcified, such that pre-dilatation cannot be performed or has failed, making the application of the investigational medical device difficult.
  • AddedPatients in whom the investigator determines that PCI cannot be performed because of the anatomical characteristics of the target vessel or lesion or the patient's clinical condition.
Oct 9, 2026
Interventions
Changed Second, Third Generation Drug-Eluting Coronary Stent System→Contemporary Drug-Eluting Stents (DES). Arm changed Second, Third Generation Drug-Eluting Coronary Stent System→Contemporary Drug-Eluting Stents (DES)
Oct 9, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameNet Clinical outcome (NCO)at 12 months after procedure → the time to the first occurrence of a Net Clinical Outcome (NCO) within 12 months after randomization.
  • DescriptionNet Clinical outcome (NCO): how it is measured was reworded
Oct 9, 2026
Contact
Study contact changed: s•••@gmail.com · •••4025→s•••@gmail.com · •••8838. See the current contact
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in South Korea
    Show site
    • Ulsan University Hospital · Ulsan, South Korea
    Start date Apr 15, 2026→Sep 28, 2026 (now actual)
    Study completion Jul 31, 2032→Dec 31, 2032
    Eligibility 5 inclusion criteria edited, 2 added, 1 removed; 6 exclusion criteria edited, 2 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • AddedPatients must meet all of the following inclusion criteria to be eligible for participation in this clinical study.
    • EditedMale or female adultsAdults aged ≥20 years or older with stable angina, silent myocardial ischemia, unstable angina, or non-ST-segment elevation myocardial infarction (NSTEMI).
    • EditedIn cases ofPatients with ST-segment elevation myocardial infarction (STEMI), patients who have undergone successful and uncomplicated primary percutaneous coronary intervention (PCI) without complications,, are at least 48 hours post-after the index procedure, and whose target lesion(s) showhave no evidence of thrombus in the lesion(s) intended for treatment.
    • EditedPatients with multivessel coronary artery disease, defined as angiographic≥50% diameter stenosis of 50%by coronary angiography, in whom the investigator determines that PCI is indicated in at least two major epicardial coronary arteries requiring PCI as determined by the investigator.
    • EditedReferencePatients with a reference vessel diameter (RVD) of the target lesion(s) between ≥2.25 mm and ≤4.0 mm, as assessed by visual estimation or quantitative coronary angiography (QCA).
    • RemovedTarget lesions suitable for treatment with either drug-eluting stents (DES) or drug-coated balloons (DCB).
    • AddedPatients in whom the investigator determines, based on coronary angiographic findings and clinical assessment, that PCI of the target lesion(s) is technically feasible.
    • EditedPatients who have voluntarily providedprovide written informed consent to participate in the clinical trial and are willing and able to comply with all protocol-specifiedthe study requirements.
    Exclusion criteria
    • AddedPatients meeting any of the following criteria will be excluded from enrollment.
    • EditedCardiogenic shock or patients requiringthe need for mechanical or pharmacological circulatory support.
    • EditedPatients with a lifeLife expectancy of less than ≤2 years due to comorbidconcomitant medical conditions.
    • ChangedBefore Patients who are currently participating or planning to participate in other interventional clinical trials, excluding observational studies.Now Current participation in, or planned participation in, another interventional clinical trial, excluding observational studies.
    • EditedWomen who are pregnantPregnant women or havewomen of childbearing potential.
    • EditedPatients with a knownKnown hypersensitivity or allergy to contrast media, L-605 Cobaltcobalt-Chromiumchromium (Co-Cr) alloy, PLA andor PLGA polymers, shellac, Vitamin E-TPGS, paclitaxel, or sirolimus.
    • EditedPatients with aA target lesion located within a saphenous vein graft (SVG) or an arterial graft.
    • RemovedPatients with target vessels/lesions that are excessively tortuous, angulated, or severely calcified, such that pre-dilatation cannot be performed or has failed, making the application of the investigational medical device difficult.
    • AddedPatients in whom the investigator determines that PCI cannot be performed because of the anatomical characteristics of the target vessel or lesion or the patient's clinical condition.
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameNet Clinical outcome (NCO)at 12 months after procedure → the time to the first occurrence of a Net Clinical Outcome (NCO) within 12 months after randomization.
    • DescriptionNet Clinical outcome (NCO): how it is measured was reworded
    Interventions Changed Second, Third Generation Drug-Eluting Coronary Stent System→Contemporary Drug-Eluting Stents (DES). Arm changed Second, Third Generation Drug-Eluting Coronary Stent System→Contemporary Drug-Eluting Stents (DES)
    Contact Study contact changed: s•••@gmail.com · •••4025→s•••@gmail.com · •••8838. See the current contact
    + 3 other changes: verification date, oversight details and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07539324
Lead sponsor
Genoss Co., Ltd.
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
Sep 28, 2026
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Oct 9, 2026

Study contacts

Eun-Seok Shin, MD, PhD
Contact
sesim1989@gmail.com
+82-52-250-8838

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion